128 related articles for article (PubMed ID: 35637134)
1. CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy.
Mikami N; Takeda A; Hashimoto A; Takeda T; Kimura Y; Oku Y; Aoki Y; Eriguchi T; Tsurugai Y; Saeki N; Enomoto T; Kuribayashi H; Masuda M; Kaneko T
Clin Lung Cancer; 2022 Jul; 23(5):428-437. PubMed ID: 35637134
[TBL] [Abstract][Full Text] [Related]
2. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity.
Onishi H; Shioyama Y; Matsumoto Y; Shibamoto Y; Miyakawa A; Suzuki G; Nishimura Y; Sasaki R; Miyawaki D; Kuriyama K; Komiyama T; Marino K; Aoki S; Saito R; Araya M; Maehata Y; Nonaka H; Tominaga L; Saito M; Sano N; Yamada S
J Radiat Res; 2020 May; 61(3):426-430. PubMed ID: 32219316
[TBL] [Abstract][Full Text] [Related]
4. CT patterns and serial CT Changes in lung Cancer patients post stereotactic body radiotherapy (SBRT).
Al-Umairi R; Tarique U; Moineddin R; Jimenez-Juan L; Kha LC; Cheung P; Oikonomou A
Cancer Imaging; 2022 Sep; 22(1):51. PubMed ID: 36114585
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience.
Jang JY; Kim SS; Song SY; Shin YS; Lee SW; Ji W; Choi CM; Choi EK
Cancer Res Treat; 2023 Oct; 55(4):1181-1189. PubMed ID: 36960626
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Med Phys; 2014 Mar; 41(3):033502. PubMed ID: 24593744
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
[TBL] [Abstract][Full Text] [Related]
8. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Starkov P; Aguilera TA; Golden DI; Shultz DB; Trakul N; Maxim PG; Le QT; Loo BW; Diehn M; Depeursinge A; Rubin DL
Br J Radiol; 2019 Feb; 92(1094):20180228. PubMed ID: 30457885
[TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Dunlap NE; Yang W; McIntosh A; Sheng K; Benedict SH; Read PW; Larner JM
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1071-7. PubMed ID: 22898383
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
12. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
15. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis.
Badiyan SN; Bierhals AJ; Olsen JR; Creach KM; Garsa AA; Dewees T; Bradley JD; Robinson CG
Radiat Oncol; 2013 Jan; 8():4. PubMed ID: 23286648
[TBL] [Abstract][Full Text] [Related]
19. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
20. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
